Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of “Moderate Buy” from Analysts

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $22.50.

A number of equities analysts have recently commented on PHAT shares. Barclays upgraded shares of Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $16.00 to $18.00 in a research report on Friday, March 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Thursday, January 22nd. Cantor Fitzgerald restated an “overweight” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, January 14th. Stifel Nicolaus set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Thursday, February 26th. Finally, Guggenheim raised their price objective on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, February 27th.

Phathom Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:PHAT opened at $12.67 on Tuesday. The firm has a market capitalization of $1.01 billion, a PE ratio of -4.14 and a beta of 0.61. Phathom Pharmaceuticals has a twelve month low of $2.21 and a twelve month high of $18.31. The company has a 50-day moving average price of $11.59 and a two-hundred day moving average price of $13.40.

Phathom Pharmaceuticals (NASDAQ:PHAT) last issued its earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $57.58 million for the quarter, compared to the consensus estimate of $57.44 million. Analysts anticipate that Phathom Pharmaceuticals will post -4.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Large investors have recently modified their holdings of the company. AIGH Capital Management LLC bought a new position in shares of Phathom Pharmaceuticals in the third quarter valued at approximately $5,049,000. Hennion & Walsh Asset Management Inc. bought a new position in shares of Phathom Pharmaceuticals in the fourth quarter valued at approximately $1,908,000. GW&K Investment Management LLC raised its stake in Phathom Pharmaceuticals by 9.1% in the third quarter. GW&K Investment Management LLC now owns 1,144,330 shares of the company’s stock valued at $13,469,000 after purchasing an additional 95,858 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Phathom Pharmaceuticals in the third quarter valued at approximately $827,000. Finally, Stratos Wealth Partners LTD. purchased a new stake in Phathom Pharmaceuticals in the fourth quarter valued at approximately $834,000. 99.01% of the stock is currently owned by institutional investors.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.